A practical reference on anti-doping analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== History == EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019. It was developed by Lizard Labs. The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.
=== Synthesis and reactions === Several methods exist for the laboratory synthesis of dimethyl fumarate, with reported methods including alkene isomerization of dimethyl maleate, and Fischer esterification of fumaric acid. Dimethyl fumarate is an old compound used in industrial chemistry and can be purchased by the ton; as of 2012, one could purchase it for $1 to $50 per metric ton, with a two-ton minimum purchase. The compound undergoes electrohydrodimerization.
As of August 13, 2020, the menu underwent another update as part of their efforts to streamline processes in their restaurants in response to the COVID-19 pandemic, discontinuing the following items: Grilled Steak Soft Taco; 7-Layer Burrito; Nachos Supreme; Beefy Fritos Burrito; Spicy Tostada; Triple Layer Nachos; Cheesy Fiesta Potatoes; Loaded Grillers, both Cheesy Potato and Beefy Nacho; Chips & Dips; and Mini Skillet Bowl.
The Wagler's pit viper is found in southern Vietnam from the provinces of Minh Hai and Song Be, in southern Thailand recorded from the provinces of Phang Nga, Phuket, Pattani, Surat Thani, Nakhon Si Tammarat, Narathiwat, and Yala, probably distributed throughout the Peninsula in west Malaysia, as well as the island of Penang, in Singapore and in Indonesia on Sumatra, the islands of the Riau Archipelago, Bangka, Billiton, Nias, the Mentawai Islands (Siberut), Natuna, and Karimata. In a revision by Vogel et al (2007), the Wagler's pit viper species complex was differentiated into several taxa, including the resurrection of T. subannulatus. The Western Philippine populations belong to T. subannulatus, but those from Mindanao include snakes assigned to both this species and T. philippensis. Tropidolaemus subannulatus has a wide distribution in Central Indonesia, Malaysia and Philippines, the Wagler's Pit Viper is restricted to mainland Southeast Asia, down to Sumatra and Bangka, West Indonesia."
This intracellular gliotoxin activates the transcription factor GliZ, facilitating gli gene cluster expression, and an enzyme called GtmA (S-adenosylmethionine (SAM)-dependent bis-thiomethyltransferase). GtmA acts as a negative regulator for gliotoxin biosynthesis by adding methyl groups to the two sulfur residues on the dithiol gliotoxin intermediate to form bisdethilobis(methylthio)-gliotoxin (BmGT). These additions prevent the formation of the disulfide bridge by GliT, inhibiting gliotoxin formation, while BmGT is significantly less toxic than gliotoxin. It is thought that GliA, GtmA, and GliT provide mechanisms for self-protection against gliotoxin toxicity for the fungi that produce and excrete gliotoxin. GliA is a transporter involved in the secretion of gliotoxin, and it has been found that depletion of the GliA protein would result in cell death in A. fumigatus and significantly increase A. fumigatus sensitivity to gliotoxin. GtmA catalyzes the addition of methyl groups to the sulfur residues of dithiol gliotoxin to form nontoxic BmGT, which reduces the toxicity load on the fungi while also downregulating further expression of the gli cluster and attenuating gliotoxin biosynthesis. GliT is required for the formation of the disulfide bridge to create active gliotoxin, but it is also suggested that it plays a role in self-protection against gliotoxin toxicity. In A. fumigatus with the deletion of the GliT gene, there was found to be an accumulation of dithiol gliotoxin, which contributed to hypersensitivity to exogenous gliotoxin.
Sources: en.wikipedia.org
Eddy stayed there for two years, from 1868 to 1870, teaching Wentworth with Quimby's unpublished essay, "Questions and Answers." She acknowledged that the manuscript was Quimby's, and spoke often of how she had promised to teach his healing method, which at the time she called Moral Science.
White adipose tissue also acts as a thermal insulator, helping to maintain body temperature. The hormone leptin is primarily manufactured in the adipocytes of white adipose tissue which also produces another hormone, asprosin.
==== Splenic sequestration crisis ==== The spleen is prone to damage in sickle cell disease due to its role as a blood filter. A splenic sequestration crisis, also known as a spleen crisis, is a medical emergency that occurs when sickled red blood cells block the spleen's filter mechanism, causing the spleen to swell and fill with blood. The accumulation of red blood cells in the spleen results in a sudden drop in circulating haemoglobin and potentially life-threatening anaemia. Symptoms include left-sided pain, swollen spleen (which can be detected by palpation), fatigue, dizziness, irritability, rapid heartbeat, or pale skin. It most commonly affects young children; the median age of first occurrence is 1.4 years. By the age of 5 years, repeated instances of sequestration cause scarring and eventual atrophy of the spleen. Treatment is supportive, with blood transfusion if haemoglobin levels fall too low. Full or partial splenectomy may be necessary. Long-term consequences of a loss of spleen function are increased susceptibility to bacterial infections.
In obesity, a decreased sensitivity to leptin occurs (similar to insulin resistance in type 2 diabetes), resulting in an inability to detect satiety despite high energy stores and high levels of leptin.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.